X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4054) 4054
Publication (236) 236
Book Review (108) 108
Magazine Article (33) 33
Book Chapter (28) 28
Trade Publication Article (13) 13
Book / eBook (11) 11
Conference Proceeding (5) 5
Newsletter (5) 5
Newspaper Article (5) 5
Data Set (3) 3
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3220) 3220
index medicus (2031) 2031
female (1618) 1618
male (1446) 1446
venous thromboembolism (1267) 1267
middle aged (1208) 1208
aged (1040) 1040
risk factors (993) 993
thromboembolism (959) 959
adult (945) 945
peripheral vascular disease (842) 842
deep-vein thrombosis (829) 829
prevention (753) 753
surgery (753) 753
venous thrombosis (753) 753
hematology (726) 726
anticoagulants - therapeutic use (710) 710
thrombosis (703) 703
pulmonary-embolism (581) 581
treatment outcome (559) 559
pulmonary embolism (524) 524
anticoagulants (511) 511
aged, 80 and over (491) 491
retrospective studies (484) 484
medicine, general & internal (452) 452
cost-benefit analysis (443) 443
molecular-weight heparin (435) 435
risk (419) 419
prophylaxis (406) 406
venous thrombosis - prevention & control (405) 405
medicine & public health (391) 391
venous thromboembolism - prevention & control (382) 382
analysis (369) 369
care and treatment (350) 350
health aspects (340) 340
deep vein thrombosis (339) 339
mortality (331) 331
risk-factors (326) 326
management (313) 313
research (313) 313
adolescent (311) 311
venous thrombosis - drug therapy (297) 297
heparin, low-molecular-weight - therapeutic use (291) 291
diagnosis (283) 283
anticoagulants - economics (282) 282
risk assessment (281) 281
complications (279) 279
prospective studies (279) 279
deep venous thrombosis (277) 277
anticoagulants - administration & dosage (273) 273
time factors (268) 268
pharmacology & pharmacy (265) 265
venous thrombosis - etiology (265) 265
heparin (263) 263
warfarin (251) 251
enoxaparin (247) 247
patients (247) 247
venous thrombosis - economics (247) 247
incidence (244) 244
cancer (242) 242
disease (236) 236
drug therapy (235) 235
young adult (235) 235
therapy (225) 225
venous thromboembolism - epidemiology (220) 220
unfractionated heparin (215) 215
quality of life (213) 213
thromboprophylaxis (213) 213
hospitals (207) 207
united states (207) 207
venous thromboembolism - etiology (206) 206
abridged index medicus (205) 205
epidemiology (205) 205
venous thrombosis - epidemiology (203) 203
anticoagulants - adverse effects (201) 201
health care sciences & services (198) 198
oncology (195) 195
prevalence (195) 195
postoperative complications - prevention & control (194) 194
medicine (191) 191
health risk assessment (190) 190
cost-effectiveness (188) 188
venous thrombosis - diagnosis (188) 188
quality-of-life (185) 185
pulmonary embolism - prevention & control (183) 183
catheterization, central venous - adverse effects (182) 182
internal medicine (179) 179
venous thrombosis - therapy (179) 179
follow-up studies (176) 176
practice guidelines as topic (176) 176
rivaroxaban (176) 176
recurrence (172) 172
studies (168) 168
heparin - therapeutic use (167) 167
medical research (167) 167
pregnancy (166) 166
metaanalysis (165) 165
venous thromboembolism - drug therapy (164) 164
usage (163) 163
cardiology (162) 162
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4041) 4041
French (23) 23
German (21) 21
Spanish (16) 16
Portuguese (8) 8
Russian (8) 8
Japanese (4) 4
Danish (3) 3
Polish (3) 3
Chinese (2) 2
Czech (2) 2
Italian (2) 2
Dutch (1) 1
Finnish (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 04/2010, Volume 30, Issue 4, pp. 669 - 674
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 4, pp. 778 - 792
Summary The relative efficacy and safety of dabigatran etexilate and warfarin have been evaluated in two head-to-head, phase III, treatment of acute venous... 
New Technologies, Diagnostic Tools and Drugs | Economics | Anticoagulation | Venous thrombosis | Treatment | Cost-effectiveness | treatment | cost-effectiveness | THROMBOSIS | anticoagulation | RIVAROXABAN | PREVENTION | APIXABAN | ATRIAL-FIBRILLATION | STROKE | economics | RECURRENT VENOUS THROMBOEMBOLISM | PULMONARY-EMBOLISM | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | SYSTEMIC EMBOLISM | Drug Costs | Venous Thrombosis - diagnosis | Dabigatran - adverse effects | Venous Thromboembolism - mortality | Humans | Anticoagulants - economics | Warfarin - adverse effects | Warfarin - economics | Models, Economic | Dabigatran - therapeutic use | Hemorrhage - economics | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Time Factors | Venous Thromboembolism - economics | Venous Thromboembolism - diagnosis | Quality-Adjusted Life Years | Acute Disease | Drug Administration Schedule | Venous Thrombosis - drug therapy | Kaplan-Meier Estimate | Venous Thrombosis - mortality | Venous Thrombosis - economics | Anticoagulants - therapeutic use | Treatment Outcome | United Kingdom | Anticoagulants - adverse effects | Pulmonary Embolism - mortality | Pulmonary Embolism - diagnosis | Dabigatran - economics | State Medicine - economics | Cost-Benefit Analysis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Pulmonary Embolism - economics
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0135054
Journal Article